Elixir Associates reposted this
German Biotech Raises $150M for Cancer Therapy Resistance! CatalYm, a Munich-based biotech, secured $150 million in Series D funding to advance its cancer therapy, visugromab. Supported by major investors such as Novartis Venture Fund and Jeito Capital, along with new investors like Canaan Partners and Bioqube Ventures, this funding will propel visugromab into late-stage clinical trials. Visugromab, a humanized monoclonal antibody targeting GDF-15, boosts the immune system's ability to attack cancer cells by neutralizing this protein. The phase 1/2 trials presented at the ASCO Annual Meeting 2024 showed promising results, highlighting its potential to transform cancer care. #Cancer #Funding #Immunotherapy
